FIGURE 3.

Skin blood perfusion assessed as (A) laser speckle contrast imaging (LSCI) basal flow and (B) LSCI flare, erythema assessed as (C) average redness, (D) CIELab a* with multispectral imaging, (E) CIELab a* with colorimetry and (F) erythema index with ATBM 2D photography and (G) oedema height with multispectral imaging by treatment group. Treatment groups are defined as subjects receiving intramuscular (i.m.) keyhole limpet haemocyanin (KLH) immunization and intradermal (i.d.) KLH administration (n = 12), intramuscular placebo immunization and intradermal KLH administration (n = 3) and both immunization groups combined (KLH or placebo) and no intradermal administration (untreated arm; n = 15). Data are shown as change from baseline least square means (LSM) with 95% CI. * P < .05, ** P < .01 and *** P < .001